Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar 31;21(1):134.
doi: 10.1186/s12905-021-01263-y.

Recurrence characteristics and clinicopathological results of borderline ovarian tumors

Lina Niu  1 , Huihui Tian  1 , Yongjun Xu  2 , Jieqiong Cao  3 , Xu Zhang  1 , Junli Zhang  1 , Jiajia Hou  1 , Weiqin Lv  1 , Junxia Wang  1 , Li Xin  1 , XuFeng Dong  4 , Tao Xu  5 , Yuan Nan  6 , Hua Wei  1 , Xinting Chai  1 , Na Li  1 , Yan Ni  7 , Yun Shang  1 , Lizhen Zhang  1 , Ye Zhao  8
Affiliations

Recurrence characteristics and clinicopathological results of borderline ovarian tumors

Lina Niu et al. BMC Womens Health. .

Abstract

Background: This study aimed to investigate the clinical and pathological characteristics, and the recurrence and prognostic factors of borderline ovarian tumors (BOTs).

Methods: The data of 286 patients admitted to hospital and followed up for more than ten months were analyzed retrospectively to study the clinicopathological characteristics and related factors of recurrence.

Results: The median age of the patients was 42.06 ± 14.97 years, and the duration of the follow-up ranged from 10-109 months. During the follow-up period, 40 patients had a recurrence. Of these patients, 36 were ≤ 40 years, and patients with premenopausal recurrence accounted for 20.5% (36/176). In patients undergoing conservative treatment or radical operations, the recurrence rates were 21.3% and 1.8%, respectively, and they were 13.4% (36/268) in patients at Federation International of Gynecology and Obstetrics (FIGO) stage I, and 22.2% (4/18) in patients at an advanced stage. Postoperative pathology revealed that 40 patients had micropapillary tumors, among whom ten patients (25%) had a recurrence, and 19 patients had complications with interstitial infiltration. Of these 19 patients, six had a recurrence (31.5%). Another 22 patients had complications with calcified sand bodies; among these, eight patients (36.4%) had a recurrence. All the differences were statistically significant (P < 0.05). There were four cancer-related deaths during the follow-up period. Late FIGO stage, conservative operation, and a high level of carbohydrate antigen 125 (CA125) were independent risk factors for the recurrence of BOTs.

Conclusion: BOTs usually occur in women under 40 years, have an occult onset, and half of the patients have no obvious clinical manifestations. Serum CA125 level can be used as a tumor marker to detect BOTs and the risk of its recurrence. Operation mode and FIGO stage are important independent factors for the recurrence of BOTs.

Keywords: CA125; Conservative surgery; FIGO staging; Ovarian borderline tumor; Recurrence.

PubMed Disclaimer

Conflict of interest statement

All authors have contributed significantly to the manuscript and declare that the work is original and has not been submitted or published elsewhere. None of the authors have any financial disclosure or conflict of interest.

Figures

Fig. 1
Fig. 1
Difference in survival curves between the two groups
See this image and copyright information in PMC

References

    1. Kim SH. Assessment of solid components of borderline ovarian tumor and stage I carcinoma: added value of combined diffusion- and perfusion-weighted magnetic resonance imaging. Yeungnam Univ J Med. 2019;36(3):231–240. doi: 10.12701/yujm.2019.00234. - DOI - PMC - PubMed
    1. Elsherif S, Javadi S, Viswanathan C, Faria S, Bhosale P. Low-grade epithelial ovarian cancer: what a radiologist should know. Br J Radiol. 2019;92(1095):20180571. doi: 10.1259/bjr.20180571. - DOI - PMC - PubMed
    1. Guillaume A, Pirrello O. Preservation of fertility in surgery of benign and borderline malignant ovarian tumors. J Visc Surg. 2018;155(S1):S17–S21. doi: 10.1016/j.jviscsurg.2018.04.001. - DOI - PubMed
    1. Fei-Chi Analysis of prognostic factors in patients with ovarian borderline tumor. Jilin University 2020.
    1. Sozen H, Vatansever D, Topuz S, Iyibozkurt C, Kandemir H, Yalçin I, et al. Clinicopathological analysis of borderline ovarian tumours and risk factors related to recurrence: experience of single institution. J Obstet Gynaecol. 2018;39:253–258. doi: 10.1080/01443615.2018.1499076. - DOI - PubMed